Sangrado masivo en obstetricia. Estrategias de  tratamiento

Karina Rando; Martin Mojoli

doi:10.35954/SM2017.36.2.7

Autores

Karina Rando Centro Nacional Hepato-bilio-pancreático del Hospital Central de las Fuerzas Armadas. Montevideo. Uruguay. https://orcid.org/0000-0001-7397-1711
Martin Mojoli Departamento de Ginecología y Obstetricia. Hospital Central de las Fuerzas Armadas https://orcid.org/0000-0002-2418-3775

DOI:

https://doi.org/10.35954/SM2017.36.2.7

Palavras-chave:

Anestesia; Hemorragia; Pós-parto Hemorragia; Placenta previa; Transfusão de sangue

Resumo

A perda de sangue esperada é de até 500 ml no parto natural e de até 1000 ml no parto cesáreo. entrega natural e 1000 ml em cesárea. O perda maciça de sangue em obstetrícia é aquela que requer transfusão de produtos sanguíneos, a necessidade de requer transfusão de produtos sanguíneos, histerectomia ou outra emergência histerectomia ou outros procedimentos de emergência, tais como a ligadura vascular para parar como a ligação vascular para deter a perda de sangue e é uma das principais causas de morbidade e mortalidade. e é uma das principais causas de morbidade e mortalidade na mãe-filho mortalidade do par mãe-filho.
Descrevemos o caso clínico de uma mulher grávida com placenta praevia, cesárea, que apresentava sangramento em duas fases. duas etapas. Na primeira etapa, o controle cirúrgico dos danos dos tecidos foi os danos do tecido e, na segunda etapa, o paciente teve de ser estabilizado e o paciente foi estabilizado e ressuscitado antes da hemostasia cirúrgica.
Marcamos as diferenças na estratégia de reposicionamento em relação ao tipo de hemorragia. Analisamos o fatores que favorecem o sangramento e a importância da comunicação para um bem comunicação para alcançar um bom resultado materno e fetal.

Downloads

Não há dados estatísticos.

Referências

(1) Harde M, Dave S, Wagh S, Gujjar P, Bhadade R, Bapat A. Prospective evaluation of maternal morbidity and mortality in post-cesarean section patients admitted to postanesthesia intensive care unit. J Anaesthesiol Clin Pharmacol 2014; 30(4):508-13.

(2) Saad A, Costantine MM. Obstetric hemorrhage: recent advances. Clin Obstet Gynecol 2014; 57(4):791-6.

(3) Parant O, Guerby P, Bayoumeu F. Obstetric and anesthetic specificities in the management of a postpartum hemorrhage (PPH) associated with cesarean section. J Gynecol Obstet Biol Reprod (Paris) 2014; 43(10):1104-22.

(4) Irita K, Inada E, Yoshimura H, Warabi K, Tsuzaki K, Inaba S, et al. Present status of preparatory measures for massive hemorrhage and emergency blood transfusion in regional hospitals with an accredited department of anesthesiology in 2006. Masuí 2009; 58(1):109-23.

(5) Irita K, Yoshimura H, Sakaguchi Y, Takamatsu C, Tokuda K. Ri s k and c ri s i s management by anesthesiologists regarding 'Guidelines for Actions Against Intraoperative Critical Hemorrhage' published by the Japanese Society of Anesthesiologists and the Japan Society of Transfusion Medicine and Cell Therapy. Masuí 2008; 57(9):1109-16.

(6) Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol 2007; 73(7-8):401-15.

(7) Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. Br J Anaesth 2005; 95(2):130-9.

(8) Greenwood LH, Glickman MG, Schwartz PE, Morse SS, Denny DF. Obstetric and nonmalignant gynecologic

bleeding: treatment with angiographic embolization. Radiology 1987; 164(1):155-9.

(9) Santoso JT, Saunders BA, Grosshart K. Massive blood loss and transfusion in obstetrics and gynecology. Obstet Gynecol Surv 2005; 60(12):827-37.

(10) McCarthy GC, Allen TK, Habib AS. Pulmonary embolism after administration of recombinant activated Factor VII for major obstetric hemorrhage. J Clin Anesth 2012; 24(6):508-9.

(11) Snegovskikh D, Clebone A, Norwitz E. Anesthetic management of patients with placenta accreta and resuscitation strategies for associated massive hemorrhage. Curr Opin Anaesthesiol 2011; 24(3):274-81.

(12) Lupattelli A, Spigset O, Koren G, Nordeng H. Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: a study from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2014; 34(1):143-8.

(13) Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sang 2005; 89(3):123-7.

(14) Teixeira PG, Inaba K, Shulman I, Salim A, Demetriades D, Brown C, et al. Impact of plasma transfusion in massively transfused trauma patients. J Trauma 2009; 66(3):693-7.

(15) Zink KA, Sambasivan CN, Holcomb JB, Chisholm G, Schreiber MA. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg 2009; 197(5):565-70; discussion 70.

(16) Miller RD, Robbins TO, Tong MJ, Barton SL. Coagulation defects associated with massive blood transfusions. Ann Surg 1971; 174(5):794-801.

(17) Maani CV, DeSocio PA, Holcomb JB. Coagulopathy in trauma patients: what are the main influence factors? Curr Opin Anaesthesiol 2009; 22(2):255-60.

(18) Spinella PC. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study. Crit Care Med 2008; 36(7 Suppl):S340-5.

(19) Shaz BH, Dente CJ, Harris RS, MacLeod JB, Hillyer CD. Transfusion management of trauma patients. Anesth Analg 2009; 108(6):1760-8.

(20) Eddy VA, Morris JA, Jr., Cullinane DC. Hypothermia, coagulopathy, and acidosis. Surg Clin North Am 2000; 80(3):845-54.

(21) Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri J, et al. An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65(5):986-93.

(22) Gonzalez EA, Moore FA, Holcomb JB, Miller CC, Kozar RA, Todd SR, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62(1):112-9.

(23) Spinella PC, Perkins JG, Grathwohl KW, Beekley AC, Holcomb JB. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma 2009; 66(4 Suppl):S69-76.

(24) Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17(2):120-62.

(25) Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG 2014; 121(1):62-70; discussion 70-1.

(26) Johansson PI. The blood bank: from provider to partner in treatment of massively bleeding patients. Transfusion 2007; 47(2 Suppl):176S-81S; discussion 82S-83S.

(27) Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62(15):2193-211.

(28) Hasankhani H, Mohammadi E, Moazzami F, Mokhtari M, Naghgizadh M. The effects of intravenous fluids temperature on perioperative hemodynamic situation, post-operative shivering, and recovery in orthopaedic surgery. Can Oper Room Nurs J 2007; 25(1):20-4, 26-7.

(29) Zhao J, Luo AL, Xu L, Huang YG. Forced-air warming and fluid warming minimize core hypothermia during abdominal surgery. Chin Med Sci J 2005; 20(4):261-4.

(30) Moon PF, Kramer GC. Hypertonic saline-dextran resuscitation from hemorrhagic shock induces transient mixed acidosis. Crit Care Med 1995; 23(2):323-31.

(31) Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004; 139(5):552-63.

(32) Fries D, Innerhofer P, Schobersberger W. Time for changing coagulation management in trauma-related massive bleeding. Curr Opin Anaesthesiol 2009; 22(2):267-74.

(33) Ozier Y, Schlumberger S. Pharmacological approaches to reducing blood loss and transfusions in the surgical patient. Can J Anaesth 2006; 53(6 Suppl):S21-9.